N/A N=20 Amplifying Sensation in Underactive Bladder
Urinary Bladder, Underactive
Primary: Voiding Efficiency — 32; 53; 43; 46 voided percentage — p=1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=23 Autologous Muscle Derived Cells for Underactive Bladder
Urinary Retention · Urinary Incontinence
Primary: Number of Participants With Study-related Adverse Events at 6 Months — 2; 1; 1; 1 participants
N/A N=20 Hypnotherapy for Treatment of Overactive Bladder
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
N/A N=27 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Overactive Bladder
Primary: Change in the Relative Abundance of Lactobacillus — 0.143 proportion of total microbes
N/A N=18 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
N/A N=20 A Trial of Transcutaneous Nerve Stimulation for OAB
Overactive Bladder
Primary: Patient Reported Outcome Measure (Patient Percention of Bladder Condition Question) — 4; 3 units on a scale
Phase 2 N=76 Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
Detrusor Underactivity · Overactive Bladder
Primary: Changes in the Mean BCI for Male From Baseline to Week 12 — 64.604; 61.339; 75.156; 60.513 Score on a scale — p=<0.001
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
N/A N=61 Mindfulness + tDCS to Reduce Urgency Incontinence in Women
Urinary Incontinence, Urge
Primary: Feasibility of Study Procedures Measured by Percentage of Participants Starting Intervention Who Complete the Study — 100; 90.4; 100 percentage of participants who…
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 3 N=85 An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
Overactive Bladder
Primary: Average Number of Voids Per Day — NA; NA Average Number of Voids
Phase 2 N=9 Botulin-A Toxin Instillations and Overactive Bladder
Overactive Bladder · Detrusor Instability · Detrusor Hyperreflexia
Primary: Median Number of Incontinent Episodes During 24 Hours — 4; 2; 4 number of incontinent episodes — p=0.004
Phase 3 N=87 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary Incontinence
Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
N/A N=64 Enhancing Conservative Treatment for Urge Incontinence
Urinary Incontinence
Primary: Change in Incontinent Episodes Immediately Post-treatment — -88.5; -78.3 percentage change — p=.16
N/A N=50 Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
Chronic Spinal Cord Injury · Neurogenic Bladder
Primary: Number of Participants With Reduction in Bladder Medication — 19; 15 Participants
Phase 1 N=3 Two Devices for Reflex Voiding Following Spinal Cord Injury
Spinal Cord Injury · Urinary Incontinence
Primary: Number of Participants With a Change in Bladder Pressure — 0 participants